Progenics Pharmaceuticals Inc. (PGNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PGNX Stock Price Chart Interactive Chart >
PGNX Price/Volume Stats
|Current price||$4.10||52-week high||$6.37|
|Prev. close||$4.53||52-week low||$1.89|
|Day high||$4.79||Avg. volume||1,157,679|
|50-day MA||$4.05||Dividend yield||N/A|
|200-day MA||$4.61||Market Cap||355.05M|
Progenics Pharmaceuticals Inc. (PGNX) Company Bio
Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York.
Most Popular Stories View All
PGNX Latest News Stream
|Loading, please wait...|
PGNX Latest Social Stream
View Full PGNX Social Stream
Latest PGNX News From Around the Web
Below are the latest news stories about Progenics Pharmaceuticals Inc that investors may wish to consider to help them evaluate PGNX as an investment opportunity.
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.
Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P; SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P; Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P; SmallCap 600.
NEW YORK, June 16, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77.
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.
PGNX Price Returns
Continue Researching PGNXWant to do more research on Progenics Pharmaceuticals Inc's stock and its price? Try the links below:
Progenics Pharmaceuticals Inc (PGNX) Stock Price | Nasdaq
Progenics Pharmaceuticals Inc (PGNX) Stock Quote, History and News - Yahoo Finance
Progenics Pharmaceuticals Inc (PGNX) Stock Price and Basic Information | MarketWatch